REDWOOD CITY, Calif.–(BUSINESS WIRE)–#DigiMeds–Proteus Digital Health®, Inc. today announced that together with its
collaborators, the company has developed a pipeline of 31 digital
medicines for mental health, cardiovascular and metabolic conditions,
infectious diseases, and oncology.
Andrew Thompson, Chief Executive Officer of Proteus commented on why the
company is confidently investing to expand its pipeline. “Our extensive
clinical trial and commercial experience with digital medicines with
thousands of patients has been overwhelmingly positive. The products are
well accepted by consumers, secure, private, fully HIPAA compliant and
extraordinarily safe. More importantly, we have shown consistently that
patients who choose to use DigiMeds™ take them about 90% of the time,
compared to medication possession of 50% with regular drugs. Physicians
coach patients and properly titrate medicines at three times the rate
when they have accurate data on drug use and activities of daily life
that our solutions provide. This is more important than ever: on March
26, 2018 the Annals of Pharmacotherapy published a study estimating that
inappropriate drug use costs the U.S. $524.4 billion a year, about 16%
of total US healthcare spending. Wider use of digital medicines will
help many patients and will help save a lot of money.”
Proper use of medicines is especially important in the treatment of
mental health, where patients can be hospitalized if they do not
consistently use their drugs in the right dose. Proteus is working with
Otsuka Pharmaceutical Company to develop digital medicines for the
treatment of Bipolar, Schizophrenia and Major Depressive Disorder.
Otsuka received the first NDA approval for a digital medicine, ABILIFY
MYCITE® (aripiprazole tablets with sensor), in November 2017. Proteus
and Otsuka are investigating the development of additional digital
medicine products in mental health where there is the greatest patient
need, and assessing opportunities for regulatory registration.
In cardiovascular and metabolic conditions, Proteus has a panel of
15 digital medicines that can be prescribed to named patients in the
United States, prepared and delivered via specialty pharmacy services.
Health systems in the US have entered into master service agreements to
use the digital medicines, focusing on high-risk patients who are
failing drug therapy. Proteus has conducted several clinical studies
demonstrating the clinical and economic benefits of using digital
medicines to improve outcomes in these patients, including a successful
randomized control trial in patients with uncontrolled hypertension and
type 2 diabetes (J
Med Internet Res 2017;19(7):e246).
In infectious disease, the company has seven digital medicines that are
being used in clinical studies to treat patients with TB, hepatitis C
and HIV. These programs are designed to demonstrate that digital
medicines effectively support expanded access to curative or life
sustaining drug therapies, ensuring excellent medication adherence with
high levels of patient autonomy and satisfaction. UC San Diego TB
researcher, Dr. Sara Browne, recently completed a randomized control
trial comparing digital medicines-enabled Wirelessly Observed Therapy
(WOT) to Directly Observed Therapy (DOT), finding that WOT detected 54%
more doses than DOT while freeing patients from onerous direct
Proteus is developing a portfolio of digital medicines to help cancer
patients. These DigiMeds™ include oral oncology agents that require
complex dosing, as well as drugs intended to help alleviate side
effects, including opioid analgesics. An advisor in this initiative is
Dr. Linda Sutton, an Associate Professor of Medicine at the Duke
University School of Medicine.
“Proteus technology has the potential to improve the quality of cancer
care and make the work of cancer treatment teams timelier, more precise
and more effective,” said Dr. Sutton. “The explosion of therapeutic
options with new drugs, as well as new molecular and genetic tests, has
made oncology care increasingly complicated. We need the ability to
support patient use of drugs in the right dose, on the right
schedule, and ensure that these powerful medications are working as
intended. There is so much uncertainty when prescribing oral oncolytics
today. We send patients out of the clinic with prescriptions to fill and
take at home, and oncology teams are challenged to guide patients
through their treatment remotely. With digital oral chemotherapy drugs,
the patient’s oncologist will know with certainty when the patient took
his or her chemo. That puts the oncologist in a better position to
determine if subsequent problems are related to disease progression or
drug toxicity, and better able to assess drug efficacy.”
About Proteus Digital Health®
Proteus Digital Health is enabling a new category of pharmaceutical:
Digital Medicines. These offerings include widely used drugs, formulated
so they communicate when they have been swallowed; a wearable patch that
detects medicines and captures physiologic response; mobile applications
to support patient self-care and physician decision-making; and data
analytics to serve the needs of health system managers. The company has
more than 440 issued patents that protect this enabling technology, and
regulatory clearances in the U.S., European Union and China.
Proteus Digital Health is privately held by investors that include
Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®,
Novartis®, Otsuka, PepsiCo, and ON Semiconductor®.
Further information is available at: www.proteus.com.
Connect with us on Twitter @ProteusDH.
Proteus Digital Health® is a registered trademark owned by Proteus
Digital Health, Inc.. Abilify MyCite® is a registered trademark owned by
Otsuka Pharmaceutical Co. Ltd.
Proteus Digital Health, Inc.
Emily Fox, +1 650-637-6240